SOURCE: Skystar Bio-Pharmaceutical

December 18, 2006 13:27 ET

Skystar Bio-Pharmaceutical Hits CEOCorner at

HUNTINGTON BEACH, CA -- (MARKET WIRE) -- December 18, 2006 -- InvestSource, Inc. announced today that one of its clients, Skystar Bio-Pharmaceutical (OTCBB: SKBI), was recently featured in an interview on CEOCorner, "The Fastest 60 Seconds in the Small Cap Market." Mr. Scott Cramer, Director of Investor Relations of Skystar Bio-Pharmaceutical, took time out of his hectic schedule to give the interview. Details of the interview are available on the Skystar Bio-Pharmaceutical profile on the InvestSource, Inc. (ISI) website at:, and on the CEOCorner website at:

Over the course of the interview, Mr. Cramer was careful to point out the strong revenue and earnings performance of the company. In the third quarter of 2006, Skystar realized 118% increase in revenues, 53% increase in net income and 50% increase in EPS from the same period a year ago. Mr. Cramer touched on some of the reasons behind this tremendous growth including recent developments in the Chinese bio-pharmaceutical industry that have eliminated a large percentage of the company's competition. He was eager to stress the successful track record of Skystar as the company leaps forward to becoming the leader in its industry. For more information, visit the company website at:

About Skystar Bio-Pharmaceutical:

Skystar Bio-Pharmaceutical Company is a China-based producer and distributor of vaccines, microorganisms and 100% organic herbal additives to cure and prevent disease in poultry, livestock, birds and pets. The company's product line consists of more than 70 state-of-the-art products with over 50 additional products in the developmental stage. One of the prominent products currently in the development stage is a feed additive and vaccine for Avian Influenza. Skystar has formed strategic sales distribution networks in 27 provinces and regions throughout China. Skystar recently completed construction of new state-of-the-art Bio-Pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of the Company's products, the competitive environment within the industry, the ability of the Company to continue to expand its operations, the level of costs incurred in connection with the Company's expansion efforts, economic conditions in the industry and the financial strength of the Company's customers and suppliers. The Company does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties. The accuracy and timeliness of such data and information, including issues of translation and currency conversion, can be subject to further review and research in order to conform to the generally accepted financial practices in the U.S. The company's entire operation is in China where certain political and economic policies of the government and certain natural disasters might affect the outcome of the envisioned business.

Contact Information